Dr. Nicole Ezer is helping lead a trial with ciclesonide that promises to reduce symptoms of COVID-19. Read our initial posts about the trial here: Ciclesonide Clinical Trial for COVID-19 and ‘Contain COVID-19’ – in its earliest phases.
The Journal de Montreal reports the pursuits of our Quebec researchers and physicians in leading this trial. Ciclesonide has both anti-viral and anti-inflammatory properties. Of the few trials testing ciclesonide, the one led here at the MUHC is the only one that is studying the administration of the drug by nasal spray and inhaler. Inhalers and sprays have the advantage of acting directly in the nose, the airways, and the lungs, right were the SARS-CoV-2 virus is actually replicating. The goal of the trial is to determine whether ciclesonide reduces respiratory symptoms and in turn reduces hospitalizations.
Dr. Ezer is an Assistant Professor in the Department of Medicine at McGill University and a Junior Scientist with the RI-MUHC RESP Program.
To learn more about the trial or participate and the entire research team: www.contain-covid19.com/contenez-la-covid-19/
Read the article:
COVID-19: un vaporisateur nasal en renfort. par Stéphanie Martin, Journal de Montréal. December 31, 2020.